Canadian Regulator Reviewing Prexige Safety

Drug Industry Daily
A A
Health Canada announced it is reviewing new safety information on serious liver adverse events in patients using Novartis’ Cox-2 inhibitor Prexige, a treatment for osteoarthritis.

To View This Article:

Login

Subscribe To Drug Industry Daily